Anti-inflammatory Compounds

Following the 2014 FDA-approval of OTEZLA® (apremilast), Celgene is continuing to develop novel orally available small molecules that inhibit the production of multiple pro-inflammatory mediators.

Celgene is continuing to develop novel orally available small molecules that inhibit the production of multiple pro-inflammatory mediators.

This includes interleukin-2 (IL-2), IL-12, interferon-gamma, TNF-alpha, leukotrienes and nitric oxide synthase.

Our lead investigational product, GED-0301, an oligonucleotide that targets the messenger RNA for Smad7, is currently in clinical trials for Crohn’s disease.

GED-0301 is an investigational product and is not approved for any indication.